Log In
Print
BCIQ
Print
Print this Print this
 

odanacatib (formerly MK-0822)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionCathepsin K inhibitor
Molecular Target Cathepsin K (CTSK)
Mechanism of ActionCathepsin K inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationOsteoporosis
Indication DetailsTreat osteoporosis
Regulatory Designation

Partner

Quest Diagnostics Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today